Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.

A CGM helps me run marathons and do epic bike rides better than ever.

A few weeks ago, an allergist prescribed a two-week course of an oral steroid to clear up my sinus inflammation. Before I ...

Glucose monitoring without piercing the skin is a prize companies like Apple and Samsung have been aiming for. Now, Samsung ...

Our expert, award-winning staff selects the products we cover and rigorously researches and tests our top picks. If you buy through our links, we may get a commission. During her time at CNET, Kim ...

Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...

Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...

"Beta Bionics joins IPO uptick, aims to raise $114.4m in Nasdaq listing" was originally created and published by Medical ...

Medical device and healthcare company Abbott has opened a new facility in Kilkenny, which is expected to employ 800 people.